SNCB and Alzheimer disease: β-synuclein, encoded by SNCB, inhibits α-synuclein aggregation [149] and α-synuclein oligomer formation [150], and cortical β-synuclein levels are reduced in diffuse Lewy body disease without comorbid AD pathology [151].